Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.82 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.82 |
| ▸ | CDK2 | P24941 | 9/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 8/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.47 |
| ▸ | PI4KA | P42356 | 2/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | MGMT | P16455 | 5/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,6-Diaminopurine SCHEMBL24053 | 0.91 | PDPK1 (1.00) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL27891733 | 0.89 | PDPK1 (0.96) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL28206545 | 0.89 | PDPK1 (0.96) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL8757979 | 0.89 | PDPK1 (0.96) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL29143272 | 0.87 | PDPK1 (0.92) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL3238169 | 0.84 | PDPK1 (0.79) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL4535059 | 0.84 | PDPK1 (0.79) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL30680639 | 0.84 | PDPK1 (0.79) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL13857840 | 0.84 | PDPK1 (0.79) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL28083713 | 0.84 | PDPK1 (0.79) | PDPK1GDACDK2DPP4MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178710-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-07-12 | — | — | US | claimed |
| EP-2448954-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | Rutgers, The State University of New Jersey (US) | 2012-05-09 | — | — | EP | claimed |
| WO-2011003025-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-01-06 | — | — | WO | claimed |
| US-12503698-B2 | GalNAc derivatives | Janssen Pharmaceuticals, Inc. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250368996-A1 | MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR TREATING HEPATITIS B VIRUS | ALIGOS THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| EP-3765476-B1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-26 | — | — | EP | disclosed |
| US-20250092400-A1 | Modified Oligonucleotides and Methods of Use | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-20 | — | — | US | disclosed |
| EP-4493694-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-119032175-A | Modified spacer oligomers and methods of use thereof | 阿利戈斯治疗公司 | 2024-11-26 | — | — | CN | disclosed |
| US-12077757-B2 | Modified oligonucleotides and methods of use | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-03 | — | — | US | disclosed |
| US-20240011029-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-11 | — | — | US | disclosed |
| US-5891684-A | RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5879938-A | RIBOZYME WITH INCREASED ACTIVITY BY SUBSTITUTION OF MODIFIED NUCLEOTIDE INTO SUBSTRATE BINDING ARM OR CATALYTIC CORE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5767263-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0799313-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5672501-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5672511-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| EP-0728204-A1 | BASE-MODIFIED ENZYMATIC NUCLEIC ACID | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-08-28 | — | — | EP | disclosed |
| WO-1996018736-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-06-20 | — | — | WO | disclosed |
| WO-1995013378-A1 | BASE-MODIFIED ENZYMATIC NUCLEIC ACID | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503698-B2 | GalNAc derivatives | B3GAT3, FUT6, CSGALNACT1 | PDPK1 3401/4885GDA 56/4885CDK2 3621/4885 |
| US-20250368996-A1 | MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR TREATING HEPATITIS B VIRUS | HAVCR2, SNRPB2, NSUN2 | PDPK1 4624/4885GDA 684/4885CDK2 3792/4885 |
| US-12077757-B2 | Modified oligonucleotides and methods of use | NSUN2, ADAR, POLM | PDPK1 3984/4885GDA 194/4885CDK2 3199/4885 |
| US-20120178710-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | TYMP, DTYMK, MTAP | PDPK1 1712/4885GDA 10/4885CDK2 1782/4885 |
| US-20240011029-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | MAPT, PSEN2, NSUN2 | PDPK1 3659/4885GDA 618/4885CDK2 4200/4885 |
| US-20250092400-A1 | Modified Oligonucleotides and Methods of Use | NSUN2, ADAR, POLM | PDPK1 4059/4885GDA 189/4885CDK2 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.